We are always looking to connect with other organizations that share our mission to transform the lives of patients with cancer. Our partnering strategy focuses on expanding our ability to deliver novel cancer therapies that meet the needs of patients with aggressive cancers.
We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, in November 2017.
We are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis’ B-cell maturation antigen, or BCMA, targeting therapies, since 2018.
We actively seek collaboration or licensing opportunities that align with our pipeline, in preclinical and clinical stage.
Asset Licensing: Ayala is looking for oncology assets in Phase 1 or preclinical development that are developed as a monotherapy.
Combinations: We want to connect with companies that could benefit from Notch pathway inhibition by combining gamma secretase inhibitors with their therapies.